Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer

Background and PurposeA phase 2 study LAPACT indicated nab-paclitaxel plus gemcitabine (AG) improved outcomes of patients with locally advanced pancreatic cancer (LAPC). Conventional radiotherapy failed to show benefit, indicating high dose to volume with high risk of recurrence is needed. The high...

Full description

Bibliographic Details
Main Authors: Zhan Shi, Ju Yang, Weiwei Kong, Xin Qiu, Changchang Lu, Juan Liu, Baorui Liu, Juan Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
locally advanced pancreatic cancer
nab-paclitaxel
gemcitabine
hypofractionated tomotherapy
simultaneous integrated boost (SIB)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.782730/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.782730/full

Similar Items